Objective: To systematically evaluate the clinical efficacy and safety of Shengmai injection in the treatment of angina pectoris in coronary heart disease. Method: Literatures concerning randomized controlled trials(RCTs) regarding Shengmai injection in the treatment of angina pectoris in coronary heart disease were searched in CNKI

VIP

WanFang Database

CBM

PubMed

Embase and Cochrane Library. Quality of the included studies was evaluated with the method recommended in Cochrane

extracted the required information

and statistical was performed using the Review Manager 5.2 software. Result: A total of 14 RCTs with 932 participants were included

and the experimental group was 472 cases and the control group was 460 cases. Clinical effect analysis:Firstly

9 studies included compare the total clinical effective rate

the Meta-analysis indicated that Shengmai injection combined with conventional treatment with western medicine is effective in treating angina pectoris in coronary heart disease

on the basis of conventional therapy

Shengmai injection's total clinical effective rate is higher compared to the control group

there were statistically significant differences between groups[RR=1.24

95%CI(1.17

1.32)

P<0.00001]. Secondly

3 studies compared Hs-CRP and the Meta-analysis indicated that Shengmai injection combined with conventional treatment with western medicine can reduce Hs-CRP effectively[MD=-4.46

95%CI(-6.79

-2.12)

P=0.0002]. Finally

2 studies compared the rheology of blood and the Meta-analysis indicated Shengmai injection combined with conventional treatment with western medicine can reduce rheology of blood effectively[MD=-0.11

95%CI(-0.18

-0.03)

P=0.006]. Conclusion: Shengmai injection combined with conventional treatment with western medicine is effective in treating cardiovascular and cerebrovascular diseases.